Interv Akut Kardiol. 2022;21(4):240-242 | DOI: 10.36290/kar.2022.037

PARADISE-MI Angiotensin receptor - neprilysin inhibition in acute myocardial infarction

Jiří Vítovec, Lenka ©pinarová, Jindřich ©pinar
1. interní kardioangiologická klinika LF MU a Fakultní nemocnice u sv. Anny v Brně

The PARADISE-MI trial compared the efficacy of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, versus the ACE inhibitor ramipril in patients with acute myocardial infarction and reduced left ventricular ejection fraction. The trial included and randomized 5,661 patients. The primary endpoint was composite: death from cardiovascular causes or incident heart failure (hospitalization for heart failure or symptomatic outpatient heart failure) and was consistent in the two study groups, with no statistical significance.

Keywords: sacubitril, valsartan, ramipril, acute myocardial infarction, heart failure.

Accepted: December 9, 2022; Published: December 19, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinarová L, ©pinar J. PARADISE-MI Angiotensin receptor - neprilysin inhibition in acute myocardial infarction. Interv Akut Kardiol. 2022;21(4):240-242. doi: 10.36290/kar.2022.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pfeffer MA, Claggett B, Lewis EF, et al. PARADISE-MI Investigators and Committees. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508. Erratum in: N Engl J Med. 2021 Dec 30;385(27):2592. PMID: 34758252. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.